Forgot your password?

Forgot your username?

database > company
DataPhysics Research Inc.
Medical Devices & Tech
2400 Camino Ramon, Suite 125
San Ramon, CA 94583 USA
phone:925.736.5422
fax:925.830.1645
Symbol Private
Founded 2006
Employees 11
www.dpresearch.com
Research Sector Medical Devices & Tech
Summary Description
DPRs mission is to provide diagnostic radiologists and referring physicians with better patient information, organized in a more efficient manner available at the optimal time which will improve patient care, reduce errors and decrease image exam costs.
Management
Steven K. Douglas, CEO; James G. Plewa, COO; Vishwas Abhyankar, PdD., VP of Product Development; Martin J. Lipton, MD, Chief Medical Officer
Keywords
radiology, pattern recognition, MRI, CT, data physics research, 3D, automated report, anatomy imaging dashboard, advanced imaging, segmentation, voice regonition software

Comment | Printable Version | Modify profile |
Updated: Jul. 13, 2011

Description
DataPhysics Research (DPR) is launching next generation technology that will reduce the diagnosis and reporting time for MRI, CT and PET-CT examinations by almost half while helping to deliver improved patient care. The company's technology is an all software solution that advances how radiology image data is organized, managed, analyzed and reported. Cumulatively, the company�s software captures and organizes more detailed patient information and generates an automated diagnostic report that heightens physician comprehension, all the while delivering quicker turnaround in diagnosis time.
Products / Services
DPRs modularized turnkey solution streamlines multiple steps in a radiologist exam review process. Augmentor captures and organizes more detailed patient information. Automated Imaging Dashboard (AID) is driven by a proprietary indexed 3D that is created via its automated anatomy segmentation process resulting in image slice workload scalability. DPRs Active Report (AR) is an automatically generated diagnostic report that is embedded with 2D and 3D images. This next generation report heightens physician comprehension while delivering quicker turnaround time for getting the diagnosis to the patient.
Technology / Differentiation
The company's technology is an all software solution that advances how radiology image data is organized, managed, analyzed and reported. It is comprised of three core technologies: Augmentor, Anatomy Image Dashboard (AID) and Active Report (AR). AID utilizes the next generation of volumetric rendered 3D images linked in real time to the 2D slices to speed radiologists through "common read" studies.
Market / Customers
The healthcare imaging market in the U.S. is 40% of the global healthcare imaging marketplace or $250 billion. The total addressable market for CaseReader on a global basis exceeds $3 billion. DPR's targeted customer base is initially the 32,000 radiologists practicing in the U.S. who are employed or served by the larger teleradiology companies, the PACS OEM's such as GE, Philips, Siemens, Merge, McKesson, etc and those radiologists that are a part of standalone and hospital based groups.
Competitors / Substitutes / Alternatives
DPR faces competition in two of our three core technologies - AID and AR. In AR medical transcription companies Nuance and MedQuist continue to search for a solution to the long and arduous hours radiologists spend dictating findings and the drawn out turnaround times for getting the report to the referring physician and patient. Imaging software firms TeraRecon and Vital Images products are used primarily for complex cases such as Neuro and CV. Their products are kiosk based and utilize surface rendered 3D which is less accurate, more costly and outside of the radiologist workflow. CaseReader is utilized completely within the current workflow and developed to be used with all "common read" studies.
Status
DPRs has placed it's product into two large development partners and is working to test, hone and validate CaseReader in anticipation of a Q1 2011 commercial release. Patent applications have been filed and the company is one fourth of the way through an FDA 510k approval. The company is seeking $4M in funding to complete development work and speed commercialization of it's product to market on a global basis.